BDRX (Biodexa Pharmaceuticals) FFO


BDRX Biodexa Pharmaceuticals PLC BDRX
45 GF Score
Price $2.59
GF Value $2.26
Valuation Modestly Overvalued
View Full Analysis

What is Biodexa Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

BDRX
45GF Score
Biodexa Pharmaceuticals PLC BDRX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biodexa Pharmaceuticals (BDRX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of $2.59 is trading 14.6% above its estimated GF Value™ of $2.26. GuruFocus considers Biodexa Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for BDRX:

  • FFO:
  • GF Value™: $2.26 vs. price of $2.59 (14.6% above fair value)
  • GF Score™: 45/100

No single metric tells the full story. See the BDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
45GF Score

Get the complete analysis for BDRX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.59
Price
$2.26
GF Value